Semaglutide Storage and Stability: What Labeling and the Literature Describe (With Cagrilintide Context)

Storage questions about semaglutide sit at the intersection of two very different information sources. One is the approved product labeling, which is the legally authoritative statement of how a licensed manufacturer's presentation is to be kept. The other is the published scientific literature, which describes how the molecule was engineered, how peptides degrade in general, and what has been found when semaglutide-containing products are made outside the original manufacturing process. This page separates those sources explicitly, because they answer different questions. This page is for educational purposes only and is not medical advice; consult a licensed physician or pharmacist about any product, storage condition or handling question.

Why storage is a chemistry question for this molecule

Semaglutide is a chemically modified analogue of human glucagon-like peptide-1. The discovery paper describing the molecule reported that researchers introduced an α-aminoisobutyric acid substitution and a C18 fatty diacid side chain attached through a spacer, modifications intended to reduce enzymatic breakdown and promote albumin binding, producing a once-weekly glucagon-like peptide-1 analogue (PMID 26308095). A 2026 structural overview of GLP-1 analogues placed semaglutide within a broader family of lipidated and sequence-modified peptides whose design features determine how they behave both in the body and as pharmaceutical substances (PMID 42727920).

Those design choices address stability in vivo — resistance to proteases and renal clearance — rather than stability on a shelf. Shelf stability is governed by temperature, moisture, light, pH, container materials and excipients, and it is characterised by the manufacturer in formal stability programmes whose outputs appear as the storage statements on the carton, not as journal articles. It is worth stating plainly: there is comparatively little publicly indexed, semaglutide-specific shelf-stability literature, so much of what follows about powders, freezing and temperature excursions comes from general lyophilized-peptide stability science and is flagged as such.

Regulatory status and where authoritative storage information lives

Semaglutide is a prescription medicine. Approved injectable and oral presentations carry agency-reviewed labeling that specifies storage temperature ranges, in-use periods, light protection and disposal. A 2026 review of newer GLP-1-based medications for type 2 diabetes and obesity described how rapidly this class has expanded across indications and formulations (PMID 41054801), which matters here because different products from different manufacturers — and different presentations of the same molecule — do not necessarily share identical storage statements. The carton and the patient information leaflet supplied with a specific dispensed product are the governing documents, and a pharmacist is the appropriate person to interpret them.

Refrigeration: ready-to-use solutions versus lyophilized powder

Approved, ready-to-use presentations

Licensed injectable semaglutide is supplied as a sterile aqueous solution in a pen device, not as a powder requiring reconstitution. For solution products of this type, labeling conventionally specifies cold-chain storage in a refrigerator — the range printed on pharmaceutical cartons for refrigerated products is 2–8 °C (36–46 °F) — before first use, with the product kept in its original carton to protect it from light, and away from the cooling element at the back of a refrigerator where freezing can occur. After first use, labeling defines a limited in-use period during which the pen may be kept either refrigerated or within a stated room-temperature range; the length of that window and the permitted temperature band differ between products and presentations, which is why the specific carton text, rather than a general article, is the reference point. Oral semaglutide tablets carry their own, different storage statement.

Lyophilized vials and reconstituted material

Freeze-dried (lyophilized) semaglutide vials are not the approved commercial presentation; they appear in compounded and unapproved supply chains. General lyophilized-peptide stability science — not semaglutide-specific trial data — explains the usual reasoning behind how such powders are handled: removing water suppresses hydrolysis, deamidation and other water-mediated degradation pathways, so dry solids are typically stored cold and sealed against moisture ingress, while a peptide returned to aqueous solution re-enters those degradation pathways and is assigned a much shorter use period. The same general science is covered in PeptideU's broader explainer on peptide storage and stability. What that general science cannot supply is a validated, product-specific in-use period for any particular compounded vial, because that figure comes only from a stability programme run on that exact formulation and container.

Shelf life, expiry dating and what "beyond-use" means

Expiry dating on an approved medicine is an outcome of long-term and accelerated stability testing under defined storage conditions. It is not a property of the molecule in the abstract; it is a property of a formulation in a container stored as the label directs. Compounded preparations are assigned beyond-use dates instead, and those are typically shorter and derive from different regulatory frameworks. A 2024 pharmaceutical study examining the impact of manufacturing process and compounding on follow-on GLP-1 polypeptide drugs reported differences in properties and quality attributes between products, underscoring that a compounded or follow-on preparation cannot be assumed to behave like the originator product it resembles (PMID 39379664).

Room temperature and travel

Labeling for refrigerated injectable products generally permits a bounded period outside the refrigerator, and that allowance is what makes travel feasible for patients. The practical considerations commonly discussed in pharmacy practice — keeping the product in its original carton, avoiding checked luggage where cargo-hold temperatures are uncontrolled, avoiding vehicle interiors and direct sunlight, and using insulated carriers that do not place the product in direct contact with frozen gel packs — follow from general pharmaceutical cold-chain principles rather than from semaglutide-specific published experiments. Where a product has been exposed to conditions outside its labeled range, the manufacturer's medical information service and the dispensing pharmacist are the parties who can advise on whether the unit remains within specification; no article in the literature can answer that for an individual unit.

Freezing and freeze–thaw

Labeling for aqueous semaglutide pens states that the product is not to be frozen and is not to be used if it has been frozen. The underlying general protein-stability science is well established and is not semaglutide-specific: ice formation concentrates solutes in the remaining liquid phase, shifts pH, and creates ice–water interfaces at which peptides and proteins can unfold and aggregate, so repeated freeze–thaw cycling is a recognised stress condition in pharmaceutical development. Lipidated peptides such as the GLP-1 analogues described in the 2026 structural overview have surfactant-like amphiphilic character that makes interface-driven aggregation a relevant consideration in formulation design (PMID 42727920).

Signs of degradation described in pharmaceutical quality work

Visual inspection is the only assessment available outside a laboratory, and it detects only gross changes. In parenteral practice, a solution is expected to be clear and colourless; cloudiness, visible particulates, fibres, discolouration or a damaged container are all reasons a product is set aside and the pharmacist consulted. Chemical degradation, by contrast, is frequently invisible: deamidation, oxidation and truncation change mass and charge without changing appearance, and they are detected by chromatography and mass spectrometry. That gap between what the eye can see and what an assay can measure is precisely why the 2024 analysis of follow-on GLP-1 polypeptide products examined quality attributes analytically rather than visually (PMID 39379664).

Degradation in the body versus degradation in the vial

A common point of confusion is that semaglutide's documented resistance to breakdown refers to biological environments, not storage. Researchers investigating the oral formulation reported that co-formulation with the absorption enhancer sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate raised local gastric pH and protected the peptide from proteolytic degradation while enabling transcellular absorption across the stomach epithelium (PMID 30429357). A 2024 clinical review of that absorption enhancer described the same protective mechanism as central to the oral semaglutide experience (PMID 38230324). Engineering for biological stability is an active design goal across the class; a 2025 report described computational, AI-driven de novo design of ultra long-acting GLP-1 receptor agonists (PMID 40787887). None of this work speaks to how a pen behaves in a warm car.

Compounded and unapproved preparations: What Studies Report

Because storage questions often arise around non-originator material, it is worth noting what the published quality literature found. The 2024 pharmaceutical research study of follow-on GLP-1 polypeptide drugs reported that manufacturing process and compounding influenced product properties and quality (PMID 39379664). Regulatory agencies in several jurisdictions have separately issued notices about unapproved and compounded GLP-1 products; those are regulatory actions rather than study findings, and their current status is best checked directly with the relevant agency. Questions about whether any specific product is appropriate are matters for a prescribing clinician.

Cagrilintide context

Cagrilintide is a long-acting amylin analogue that has been studied in combination with semaglutide; the 2026 review of newer GLP-1-based medications for type 2 diabetes and obesity situated such combination approaches within the developing treatment landscape (PMID 41054801). As an investigational agent, cagrilintide has no consumer-facing approved storage label; material used in clinical trials is handled under the sponsor's investigational product manual and pharmacy protocol, which is not public literature. No published shelf-stability dataset for cagrilintide was available among the sources reviewed here, so any statement about how it should be kept outside a trial setting would be extrapolation rather than evidence.

Storage scenarios at a glance

Related reading

• General peptide storage and stability science
• Semaglutide: what the literature covers

Every question about whether a particular unit is suitable, how long it has been out of refrigeration, or what to do after a temperature excursion is a clinical and pharmaceutical question for a licensed prescriber, pharmacist or the manufacturer's medical information line.

References

• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Journal of Medicinal Chemistry, 2015)
• Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist (Science Translational Medicine, 2018)
• Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience (Clinical Diabetes, 2024)
• Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (Pharmaceutical Research, 2024)
• AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists (Advanced Science, 2025)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Structural Overview of GLP-1 Analogs (Biomedical Journal, 2026)